

AMENDMENTS TO THE SPECIFICATION

At page 1, please replace the first paragraph with the following amended paragraph:

This application is a continuation of U.S. Patent Application No. 09/445,160, which was filed on March 10, 2000, and issued as U.S. Patent No. 6,680,296, on January 20, 2002.

At page 9, please replace the figure legend starting at line 33 with the following replacement figure legend:

Figure 3 shows a comparison of the N-terminal amino acid sequence of bouganin with a number of other type-1 RIP. Bouganin (SEQ ID No. 1), gelonin (SEQ ID No. 10), momorcharin (SEQ ID No. 11), trichosanthin (SEQ ID No. 12), MAP (SEQ ID No. 13), saporin (SEQ ID No. 14), bryodin2 (SEQ ID No. 15), bryodin1 (SEQ ID No. 16), ricin A (SEQ ID No. 17), luffin A (SEQ ID No. 18), mormordin (SEQ ID No. 19), PAPS (SEQ ID No. 20), dodecandrin (SEQ ID No. 21), B. rubra RIP 2 (SEQ ID No. 22), B. rubra RIP 3 (SEQ ID No. 23), BRIP (SEQ ID No. 24). Amino acids are denoted by the single letter code.

At page 14, please replace Table 2 with the following amended table:

Table 2
Effect of *B. Spectabilis* RIP on protein synthesis by cell lines^a

Cell line	Origin	Incorporation of [³ H] leucine by control cells (dpm ± SD)	Inhibition of protein synthesis (IC ₅₀ ^b) (ng/ml)
JM	monocytes	8555 ± 824	1218 ± 484
HeLa	carcinoma	24082 ± 6367	>3300
NB100	neuroblastoma	12607 ± 3694	665 ± 0
BeWo	chorion carcinoma	18995 ± 7332	950 ± 16
3T3	fibroblasts	4317 ± 2652	>3300